Agilent Technologies Inc. (NYSE:A) today introduced the 1260 Infinity bio-inert quaternary liquid chromatography (LC) system designed to characterize and confirm large biomolecules, especially new biological entities (NBEs) and therapeutic monoclonal antibodies.
“This new system is a complete solution for addressing the growing demand to analyze NBEs and biosimilars, as drug developers seek to determine safety and efficacy of these complex molecules,” said Stefan Schuette, Agilent LC marketing director. “There are huge benefits to increasing robustness and performance significantly for large biomolecule analysis, increasing productivity, uptime and reproducibility. We think users will agree that this new system succeeds.”
The system is based on the new Agilent 1260 Infinity LC system with quaternary pump module. It features a completely inert, metal-free sample-flow path, and a stainless steel-free solvent delivery path to protect sample integrity and to minimize unspecific surface interaction and corrosion of the instrument. The system tolerates a very wide pH range from 1 to as high as 14. Agilent also offers a family of BioHPLC ion exchange and size exclusion columns designed for these specific types of analyses, contributing to the robust, reproducible high-resolution performance.
The standard detector and the 600-bar power range combine to provide the lowest detection limits and highest resolution per time for any bio-inert LC-based bioseparation system, from low-pressure methods up through small-particle, high-pressure column technology.
The new Agilent bio-inert LC system can accommodate both bioanalysis and bio-purification tasks, offering analytical flow rates and fraction collection as high as 10 ml/min.